Stockscreener 앱 받기
6.98
1.97%
-0.14
시간 외 거래:
6.98
Climb Bio Inc 주식(CLYM)의 최신 뉴스
Climb Bio (NASDAQ:CLYM) Upgraded by Truist Financial to Strong-Buy Rating - MarketBeat
Piper Sandler initiates coverage of Climb Bio (CLYM) with overweight recommendation - MSN
Is Climb Bio, Inc. (CLYM) Outperforming Other Medical Stocks This Year? - MSN
Climb Bio (CLYM) Receives 'Buy' Rating from Truist Securities | - GuruFocus
This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Sahm
Truist initiates Climb Bio stock with buy rating on drug potential - Investing.com
Climb Bio (CLYM) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Climb Bio Highlights Budoprutug and CLYM116 Milestones, Sets Up “Rich Data Year” in 2026 - Yahoo Finance
HC Wainwright Has Pessimistic View of Climb Bio Q1 Earnings - Defense World
Pharma News: Will Climb Bio Inc benefit from green energy policiesMarket Risk Report & Growth-Oriented Investment Plans - baoquankhu1.vn
Targets Report: Can Climb Bio Inc sustain its profitability2026 Action & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Raymond James initiates coverage of Climb Bio (CLYM) with strong buy recommendation - MSN
What is HC Wainwright's Forecast for Climb Bio Q1 Earnings? - MarketBeat
Analysts’ Weekly Ratings Updates for Climb Bio (CLYM) - Defense World
Raymond James starts Climb Bio, Inc. (CLYM) at Strong Buy March 2026 - Meyka
Research Analysts Issue Forecasts for Climb Bio Q1 Earnings - Defense World
Climb Bio (NASDAQ:CLYM) Shares Gap Up Following Analyst Upgrade - MarketBeat
Q1 Earnings Forecast for Climb Bio Issued By HC Wainwright - MarketBeat
Raymond James initiates Climb Bio stock coverage with strong buy on renal pipeline - Investing.com UK
Raymond James initiates Climb Bio stock coverage with strong buy on renal pipeline By Investing.com - Investing.com South Africa
Climb Bio (NASDAQ:CLYM) Hits New 52-Week High After Analyst Upgrade - MarketBeat
Climb Bio (NASDAQ:CLYM) Price Target Raised to $15.00 - MarketBeat
Climb Bio price target raised to $11 from $9 at HC Wainwright - MSN
Climb Bio (NASDAQ:CLYM) Research Coverage Started at Wedbush - Defense World
Published on: 2026-03-08 04:23:03 - baoquankhu1.vn
HC Wainwright forecasts 2026 data readouts for Climb Bio’s (CLYM) Budoprutug across clinical tracks - MSN
Analysts Offer Insights on Healthcare Companies: Climb Bio (CLYM), ArriVent BioPharma, Inc. (AVBP) and Contineum Therapeutics, Inc. Class A (CTNM) - The Globe and Mail
Fed Meeting: Is Climb Bio Inc a stock for growth or value investors2025 Biggest Moves & Consistent Income Trade Ideas - baoquankhu1.vn
Climb Bio (NASDAQ:CLYM) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPS - MarketBeat
Wedbush Raises Price Target for CLYM, Maintains 'Outperform' Rat - GuruFocus
Baird Maintains "Outperform" Rating, Raises Price Target for CLY - GuruFocus
Climb Bio (NASDAQ:CLYM) Price Target Raised to $12.00 - MarketBeat
Climb Bio Stock Pre-Market (+6.4%): Wedbush Initiates at Outperform, $12 Target - Trefis
Investment Recap: What is the Moat Score of Climb Bio Inc2025 Growth vs Value & Real-Time Buy Signal Notifications - baoquankhu1.vn
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - Sahm
Wedbush Begins Coverage on Climb Bio (NASDAQ:CLYM) - MarketBeat
Wedbush initiates Climb Bio stock with Outperform rating By Investing.com - Investing.com Nigeria
Wedbush initiates Climb Bio stock with Outperform rating - Investing.com India
Wedbush Initiates Climb Bio at Outperform With $12 Price Target - marketscreener.com
Climb 2025 10-K: $0 Revenue, $(0.88) EPS and $59.9M Net Loss - TradingView
CLYM: Net loss narrowed to $59.9M in 2025 as clinical R&D spending accelerated - TradingView
Climb Bio (Nasdaq: CLYM) ends 2025 with $160.7M cash and key 2026 trial readouts ahead - Stock Titan
Aug PostEarnings: Does Climb Bio Inc offer margin of safetyJuly 2025 Highlights & Detailed Earnings Play Alerts - baoquankhu1.vn
Climb Bio, Inc. (NASDAQ:CLYM) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Climb Bio, Inc. (NASDAQ:CLYM) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Insider Sell Alert: Stephen Thomas Sells 50,000 Shares of Climb Bio Inc (CLYM) - GuruFocus
Director at Climb Bio (CLYM) sells 50,000 shares in planned trades - Stock Titan
Climb Bio Highlights 2025 Data Catalysts, CD19 and APRIL Programs at Oppenheimer Conference - MarketBeat
1.20%
0.06%
자본화:
|
볼륨(24시간):